iShares 0 3 Month Treasury Bond ETF vs Sanofi SA — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52, while Sanofi SA trades at $43.62 (market cap $104.30B). The key difference: Sanofi SA pays a 5.55% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SGOV | SNY | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $100.74 | $52.34 |
52-Week Low | $100.28 | $41.33 |
Market Cap | — | $104.30B |
Enterprise Value | — | $124.19B |
Dividend Yield | — | 5.55% |
Signals from Pluang's Aura AI — not financial advice
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.515 with minimal daily movement (+0.01%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators are neutral. Recent institutional activity shows mixed positioning with some firms increasing stakes while others reduced exposure. The fund provides exposure to ultra-short-term Treasury bonds with monthly distributions, currently yielding approximately 3.8%.
SGOV serves as a defensive cash alternative amid market volatility, offering principal protection and minimal interest rate risk. The fund benefits from rising benchmark rates but faces pressure from potential Fed rate hikes and inflation concerns. Current macro uncertainty and steepened yield curve create both opportunity and risk for Treasury-focused investors.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Trailing returns across standard periods
Latest headlines on both assets
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →